Guide · Sectors
Life Sciences and Health
Life sciences companies in Canada need Health Canada approval to sell, PMPRB compliance to price patented medicines, and provincial listings to be reimbursed, while patents, PM(NOC) and data protection shape competition. This guide explains each stage for drugs, biologics, devices and digital health, plus transactions, privacy and litigation.
Key takeaways
- Drugs need a Health Canada notice of compliance; Class II–IV devices need a licence.
- Data protection bars generic filings for six years and approval for eight years.
- PM(NOC) actions must start within 45 days and trigger a 24-month stay.
- Methods of medical treatment are not patentable after Pharmascience, 2026 SCC 26.
- Reimbursement runs through Canada's Drug Agency or INESSS, the pCPA and provincial formularies.
Life sciences regulation in Canada at a glance
Life sciences companies in Canada work within a two-level system. Health Canada, under the federal Food and Drugs Act and its regulations, decides whether drugs, biologics, medical devices and natural health products can be sold. The Patented Medicine Prices Review Board (PMPRB) reviews the prices of patented medicines to prevent excessive pricing. Patent law, the Patented Medicines (Notice of Compliance) Regulations and data protection determine when generic and biosimilar competitors can enter. The provinces and territories then decide whether to reimburse products under public drug plans and how health services are delivered, and they regulate health professions and much of health data privacy.

This page explains each stage of the product life cycle for pharmaceutical, biotechnology, medical device and digital health companies, and the transactional and investment issues that arise. It is written for Canadian companies and for foreign companies planning a Canadian launch.
| Stage | Key rule | Source |
|---|---|---|
| Market authorization | Notice of compliance (drugs) or licence (Class II–IV devices) from Health Canada | Food and Drug Regulations; Medical Devices Regulations |
| Data protection | No abbreviated filing for six years; no approval for eight years (eight and a half with pediatric data) | Food and Drug Regulations, s. C.08.004.1 |
| Patent linkage | Innovator action within 45 days of a notice of allegation; 24-month stay | PM(NOC) Regulations, ss. 6(1), 7(1)(d) |
| Supplementary protection | Certificate of up to two years for eligible drug patents | Patent Act, s. 116(3) |
| Methods of medical treatment | Not patentable | Pharmascience Inc. v. Janssen Inc., 2026 SCC 26 |
Health Canada approvals for drugs and biologics
A new drug cannot be sold in Canada until Health Canada issues a notice of compliance (NOC) and a drug identification number. Innovators file a new drug submission with evidence of safety, efficacy and quality, and generics file an abbreviated new drug submission relying on bioequivalence. Biologics and biosimilars follow similar pathways with specific data requirements. Priority review, notices of compliance with conditions and other mechanisms can speed access for serious conditions, and Health Canada participates in international work-sharing with regulators in other countries.
Clinical trials of drugs in Canada require a clinical trial application under Part C, Division 5 of the Food and Drug Regulations, with Health Canada review and research ethics board approval. Manufacturers, importers, distributors and testers need drug establishment licences and must comply with good manufacturing practices. Post-market obligations include adverse reaction reporting, recalls and, for serious risks, the powers introduced by Vanessa's Law to require label changes and recalls.
Advertising and promotion
Advertising of prescription drugs to the general public is restricted in Canada to name, price and quantity, and promotion to health professionals must be consistent with the approved product monograph. Industry codes of practice and independent advertising preclearance agencies play a significant role in day-to-day compliance. Natural health products and medical devices have their own advertising rules. Misleading claims can also attract Competition Act enforcement.
Medical devices and digital health
Medical devices are classified into four classes under the Medical Devices Regulations according to risk, from Class I (lowest) to Class IV (highest). Class II, III and IV devices need a medical device licence from Health Canada before sale, supported by evidence that increases with the class, and manufacturers of those devices must have a quality management system certified under the Medical Device Single Audit Program. Importers and distributors of Class I devices and of other devices in some cases need a medical device establishment licence.
Software can be a medical device when it is intended for a medical purpose, such as diagnosis or treatment. Health Canada has issued guidance on software as a medical device and on machine learning-enabled medical devices, including the use of predetermined change control plans for adaptive algorithms. Digital health companies must also navigate provincial health information privacy statutes, such as Ontario's Personal Health Information Protection Act, 2004, and procurement processes of provincial health systems.
Pricing and reimbursement
The PMPRB reviews the prices of patented medicines sold in Canada to ensure they are not excessive, using factors set out in the Patent Act and its regulations and its own guidelines. Patentees must file price and sales information. The PMPRB's regulatory and guideline framework has changed significantly in recent years, so companies should apply the guidelines currently in force and track any further changes.
Reimbursement is decided separately. Canada's Drug Agency conducts health technology assessments and makes reimbursement recommendations to participating public drug plans, and Quebec's Institut national d'excellence en santé et en services sociaux (INESSS) performs this role in Quebec. The pan-Canadian Pharmaceutical Alliance negotiates prices with manufacturers on behalf of public plans, after which provinces list products on their formularies. Private insurers make their own decisions. The federal Pharmacare Act, enacted in 2024, provides a framework for national pharmacare beginning with contraception and diabetes medications through agreements with provinces and territories.
Plan pricing and reimbursement in parallel with the regulatory submission, not after approval. The price you report to the PMPRB, the health technology assessment and the pan-Canadian negotiation all interact, and inconsistent positions can delay public coverage for months.
Patents, PM(NOC) and data protection
Exclusivity for life sciences products in Canada comes from patents, certificates of supplementary protection and regulatory data protection. Under s. C.08.004.1 of the Food and Drug Regulations, a subsequent manufacturer cannot file an abbreviated submission relying on an innovative drug's data for six years after the innovator's first notice of compliance, and Health Canada cannot approve it until eight years have passed, extended to eight years and six months where qualifying pediatric studies were provided.
Under the PM(NOC) Regulations, a generic or biosimilar that refers to an innovator's drug must address patents on Health Canada's Patent Register. The innovator has 45 days after service of a notice of allegation to sue for a declaration of infringement in the Federal Court, triggering a stay of up to 24 months on the generic's notice of compliance. Certificates of supplementary protection under the Patent Act can add up to two years of protection for eligible medicinal ingredients. In Pharmascience Inc. v. Janssen Inc., 2026 SCC 26, the Supreme Court confirmed that methods of medical treatment are not patentable, which affects how dosage regimen claims are drafted. Our patents page and PM(NOC) actions insight explain the details.
Biosimilars and generic entry strategy
Generic and biosimilar companies plan their entry around the end of data protection, the expiry or invalidity of listed patents and the PM(NOC) timeline. Because the innovator's action triggers a stay of up to 24 months, generics typically serve notices of allegation well in advance of their intended launch, and they may also pursue impeachment actions in the Federal Court to clear patents that are not listed. Biosimilar uptake also depends on provincial switching policies, which several provinces have adopted for public plan beneficiaries. Innovators, for their part, manage life cycle strategy through new indications, formulations and patents, within the limits set by patentability rules.
Health data and privacy
Health information is among the most sensitive personal information. Provincial health information statutes govern custodians such as hospitals, physicians and pharmacies, while private-sector privacy laws, including PIPEDA and Quebec's Law 25, apply to many life sciences companies handling patient data, for example in patient support programmes, real-world evidence studies and digital health apps. Quebec has its own statute on health and social services information. Consent, de-identification, cross-border transfers and security are the central issues, and research uses may require research ethics board approval and data access agreements. Our privacy and data protection page compares the regimes.
Natural health products and cannabis
Natural health products, such as vitamins, herbal remedies and probiotics, require a product licence under the Natural Health Products Regulations, and site licences for manufacturers, packagers, labellers and importers. Recent changes have brought natural health products closer to drug-like oversight, including powers to require label changes and recalls. Cannabis for medical and non-medical use is regulated under the Cannabis Act, with Health Canada licensing producers and processors. Our cannabis, gaming and sports page covers that regime.
Life sciences transactions and investment
Life sciences transactions in Canada include licensing and collaboration agreements, asset purchases of product rights, acquisitions of biotech and device companies, contract manufacturing and supply agreements, and royalty monetizations. Due diligence focuses on regulatory status and compliance history, the patent and data protection position, PM(NOC) litigation, PMPRB filings and pricing commitments, reimbursement status, clinical trial data integrity, and product liability. Transfers of drug identification numbers, medical device licences and establishment licences require Health Canada filings and should be planned as closing deliverables.
Foreign investment review can apply. Biotechnology and life science technologies appear on the government's Sensitive Technology List under the national security guidelines updated in March 2025, and investments involving sensitive health data may attract scrutiny under the Investment Canada Act. Larger deals may also require Competition Act notification. Our mergers and acquisitions page covers deal structure.
Collaboration and licensing terms
Key terms in Canadian life sciences licences include the scope of rights and territory, development and commercialization diligence obligations, milestone and royalty payments, improvements and data ownership, regulatory responsibilities, patent prosecution and enforcement, and termination consequences. Royalties paid to non-residents may attract withholding tax, subject to treaty relief, and transfer pricing rules apply between related parties. Where a Canadian university or hospital is a party, its policies on publication, conflicts of interest and indirect costs will shape the agreement, and its consent may be needed for any later assignment of the licence in an acquisition.
Product liability and litigation
Life sciences companies face product liability claims based on negligence in design, manufacture or warning, and in Quebec on the Civil Code's warranty and manufacturer liability rules. Class actions over drugs and devices are common, especially in Quebec, Ontario and British Columbia. Provinces have also brought cost recovery claims, such as the opioid litigation in which the Supreme Court in Sanis Health Inc. v. British Columbia, 2024 SCC 40, upheld British Columbia's legislation allowing a class action on behalf of other governments. Companies should maintain strong pharmacovigilance, document labelling decisions carefully, preserve evidence early and coordinate litigation strategy across provinces. Our product liability page explains defence strategy.
Employment, research and incentives
Canada offers significant incentives for life sciences research, including the federal scientific research and experimental development tax credit, provincial credits such as those in Quebec and Ontario, and funding programmes for biomanufacturing. Universities and hospitals are major research partners, and their technology transfer policies determine ownership of inventions arising from sponsored research. Clinical trial agreements with Canadian sites should address publication rights, data ownership, indemnities and insurance. Recruiting specialized scientific talent may require business immigration, and IP assignment provisions in employment agreements should be robust.
Supply, manufacturing and shortages
Drug and device supply chains have become a regulatory priority. Manufacturers and importers must report actual and anticipated drug shortages and discontinuations to a public database within set timeframes, and Health Canada can take measures to mitigate shortages, including allowing exceptional importation. Good manufacturing practice inspections, foreign site listings and import controls apply to products made abroad. Tariffs and trade disruptions in 2025 and 2026 have raised questions about sourcing active ingredients and components, and contract manufacturing and supply agreements increasingly include provisions on dual sourcing, safety stock, tariff cost sharing and allocation during shortages.
Quebec specifics for life sciences
Quebec has a distinct life sciences environment. INESSS conducts health technology assessments for Quebec's public plan, the Régie de l'assurance maladie du Québec administers the public drug insurance plan, and Quebec has historically maintained its own listing policies. Labels, package inserts, patient materials and promotional materials must comply with the Charter of the French Language, in addition to federal bilingual labelling rules. Patient support programmes and data projects must satisfy Law 25 and Quebec's health information legislation. Quebec also offers its own research tax credits, which can make it attractive for clinical and research operations.
Launch checklist for life sciences companies
For a foreign life sciences company planning a Canadian launch, a practical sequence is:
- Confirm the regulatory pathway and timeline with Health Canada, including any pre-submission meeting.
- Establish or appoint a Canadian importer, distributor and, where required, a licensed establishment.
- List relevant patents on the Patent Register within the deadlines and assess CSP eligibility.
- Prepare PMPRB filings and pricing strategy before launch.
- Plan health technology assessment and pan-Canadian negotiations, and private payer strategy.
- Prepare bilingual labelling and French-language materials for Quebec.
- Set up pharmacovigilance, complaint handling, recall and shortage reporting procedures.
- Review privacy compliance for patient programmes and data flows.
How TRW & Co helps
We advise pharmaceutical, biotechnology, medical device and digital health companies and their investors on Canadian life sciences law. Our work includes regulatory strategy and Health Canada interactions, pricing and reimbursement planning, patent and data protection strategy, licensing and collaboration agreements, health data and privacy programmes, transactions and foreign investment review. We coordinate with registered patent agents and with litigation counsel licensed in the relevant jurisdiction where needed. This page is general information, not legal advice. To discuss a product or transaction, contact us.
Frequently asked questions
How long does data protection last for new drugs in Canada?
Under s. C.08.004.1 of the Food and Drug Regulations, a generic cannot file an abbreviated submission relying on the innovator's data for six years after the innovator's first notice of compliance, and cannot be approved for eight years, or eight years and six months if qualifying pediatric studies were provided.
Is software a medical device in Canada?
It can be. Software intended for a medical purpose, such as diagnosis, monitoring or treatment, may be a medical device under the Medical Devices Regulations and need a licence depending on its risk class. Health Canada has issued guidance on software and machine learning-enabled devices.
Who sets drug prices in Canada?
The PMPRB reviews prices of patented medicines to prevent excessive pricing. Public plan prices are negotiated by the pan-Canadian Pharmaceutical Alliance after health technology assessment by Canada's Drug Agency or INESSS, and provinces then decide on formulary listing. Private insurers make their own coverage decisions.
What happens when a generic company challenges my drug patent?
The generic serves a notice of allegation under the PM(NOC) Regulations. You have 45 days to sue in the Federal Court, which generally prevents Health Canada from approving the generic for up to 24 months while the court decides infringement and validity.
Do foreign acquisitions of Canadian biotech companies face review?
They can. Biotechnology and life science technologies are on the Sensitive Technology List used in national security reviews under the Investment Canada Act, and access to sensitive health data is a risk factor. Larger deals may also require Competition Act notification.
Sources
- Food and Drug Regulations (C.R.C., c. 870), s. C.08.004.1
- Patented Medicines (Notice of Compliance) Regulations (SOR/93-133)
- Patent Act, s. 116
- Supreme Court of Canada, Case in Brief: Pharmascience Inc. v. Janssen Inc., 2026 SCC 26
- Supreme Court of Canada, Case in Brief: Sanis Health Inc. v. British Columbia, 2024 SCC 40
General information only, not legal advice. References to statutes, courts and authorities describe published law and practice at the date shown.